| Literature DB >> 31168381 |
Annette Marie Maznyczka1,2, David Carrick1,2, Jaclyn Carberry1,2, Kenneth Mangion1,2, Margaret McEntegart1,2, Mark C Petrie1,2, Hany Eteiba1,2, Mitchell Lindsay1,2, Stuart Hood1,2, Stuart Watkins1,2, Andrew Davie1,2, Ahmed Mahrous1,2, Ian Ford3, Paul Welsh1, Naveed Sattar1, Keith G Oldroyd1,2, Colin Berry1.
Abstract
Objectives: We aimed to assess for sex differences in invasive parameters of acute microvascular reperfusion injury and infarct characteristics on cardiac MRI after ST-segment elevation myocardial infarction (STEMI).Entities:
Keywords: MRI; clinical outcomes; index of microcirculatory resistance; microvascular obstruction; myocardial infarction; sex
Year: 2019 PMID: 31168381 PMCID: PMC6519583 DOI: 10.1136/openhrt-2018-000979
Source DB: PubMed Journal: Open Heart ISSN: 2053-3624
Figure 1Consort flow diagram of the study. STEMI, ST-segment elevation myocardial infarction.
Baseline characteristics
| Characteristics* | Women (n=87) | Men (n=237) | P value |
| Age (years), mean±SD | 61.18±12.19 | 58.61±11.17 | 0.074* |
| Current smoker, n (%) | 57 (66) | 139 (59) | 0.262† |
| BMI <25 (kg/m2), n (%) | 18 (21) | 44 (19) | 0.069† |
| Hypertension, n (%) | 32 (37) | 73 (31) | 0.308† |
| Hypercholesterolaemia, n (%) | 28 (32) | 66 (28) | 0.446† |
| Diabetes mellitus, n (%) | 8 (9) | 26 (11) | 0.644† |
| Previous MI, n (%) | 5 (6) | 20 (8) | 0.421† |
| Previous PCI, n (%) | 2 (2) | 16 (7) | 0.171§ |
| Pre-infarct angina, n (%) | 9 (10) | 31 (13) | 0.507† |
| Social deprivation status, n (%): | |||
| I | 31 (36) | 81 (35) | 0.750† |
| Presenting HR (bpm), median (IQR) | 80.00 | 76.00 | 0.092‡ |
| Presenting BP <90/60 (mm Hg), n (%) | 14 (16) | 21 (9) | 0.063† |
| Ventricular fibrillation/tachycardia, n (%) | 8 (9) | 14 (6) | 0.297† |
| Symptom to reperfusion time (min), median (IQR) | 172.50 | 174.00 | 0.746‡ |
| Symptom to reperfusion time >6 hours, n (%) | 16 (20) | 41 (18) | 0.840† |
| Door-to-balloon time (min), median (IQR) | 20.00 | 19.00 | 0.477‡ |
| Killip class, n (%): | |||
| I | 65 (75) | 168(71) | 0.584† |
| Reperfusion strategy, n (%): | 0.458§ | ||
| Primary PCI | 83 (95) | 219 (92) | |
| Thrombolysis (failed/successful) | 4 (5.2) | 18 (8.8) | |
| Aspiration thrombectomy, n (%) | 57 (66) | 179 (76) | 0.073† |
| Glycoprotein IIbIIIa inhibitor, n (%) | 82 (94) | 215 (91) | 0.307† |
| ACE-I or ARB, n (%) | 85 (98) | 235 (99) | 0.293† |
| Beta-blocker, n (%) | 79 (91) | 229 (97) | |
| Statin, n (%) | 87 (100) | 237 (100) | |
| Aspirin, n (%) | 86 (99) | 237 (100) | 0.098† |
| Clopidogrel, n (%) | 86 (99) | 235 (99) | 0.799† |
| Anaemia, n (%) | 17 (20) | 41 (17) | 0.641† |
| eGFR ≥60 (mL/min/1.73 m2), n (%) | 76 (87) | 222 (94) | 0.059† |
| C-reactive protein, mg/L, median (IQR) | 4.00 | 3.00 | 0.063‡ |
| Peak troponin T, ng/L, median (IQR) | 1334.00 | 1944.50 | 0.113‡ |
| N-terminal pro-B-type natriuretic peptide, median (IQR) | 1175.00 | 701.50 | |
| N-terminal pro-B-type natriuretic peptide, median (IQR) | 230.50 | 154.00 | 0.144‡ |
Presenting HR was available in 321 subjects. Symptom-to-reperfusion time was available in 304 subjects. Door-to-balloon time was available in 305 subjects. eGFR was available in 323 subjects. C-reactive protein was available in 316 subjects. Peak troponin was available in 313 subjects. N-terminal pro-B-type natriuretic peptide results were available in 139 subjects on admission and 171 subjects at 6 months. Results of interleukin 6 were available in 139 subjects on admission and 171 subjects at 6 months. Information on anaemia was available in 324 subjects and was defined as haemoglobin<130 g/L in men or <115 g/L in women.
*Student’s t-test.
†χ2 test.
‡Mann-Whitney U test.
§Fisher’s exact test.
ACE-I, ACE inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HR, heart rate; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.
ECG, invasive coronary physiology and angiographic characteristics
| Women (n=87) | Men (n=237) | P value | |
| Number of diseased coronary arteries, n (%): | |||
| 1 | 48 (55) | 126 (53) | 0.842* |
| Culprit artery, n (%): LAD or left main | 27 (31)/0 | 93 (39)/1 (0) | |
| TIMI flow grade pre-PCI ≤1, n (%) | 65 (75) | 162 (68) | 0.268* |
| TIMI flow grade post-PCI ≤2, n (%) | 4 (5) | 19 (8) | 0.288* |
| TIMI frame count post-PCI, median (IQR) | 12.94 | 17.65 | |
| TIMI myocardial perfusion grade post-PCI, n (%): | 17 (20) | 76 (32) | |
| Culprit lesion plaque characterisation score, n (%): | 76 (87) | 193 (81) | 0.208* |
| Number of complex plaques in culprit/non-culprit coronary arteries, n (%): | 65 (75) | 180 (76) | 0.818* |
| Intraprocedural thrombotic event occurrence, n (%) | 8 (9) | 25 (11) | 0.721* |
| IMR (U), median (IQR) | 23.10 | 25.50 | 0.199† |
| IMR >40(U), n (%) | 21 (27) | 60 (28) | 0.771* |
| CFR, median (IQR) | 1.50 | 1.60 | 0.427† |
| CFR≤2, n (%) | 13 (17) | 37 (18) | 0.871* |
| ST-segment resolution, n (%): | 44 (51) | 104 (44) | 0.580* |
TIMI frame count post-PCI was available in 322 subjects. IMR was available in 289 subjects. CFR was available in 286 subjects. Information on ST-segment resolution was available in 323 subjects.
*χ2Chi-square test.
†Mann-Whitney U test.
CFR, coronary flow reserve; IMR, Index of microcirculatory resistance; LAD, left anterior descending artery; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction.
Cardiac MRI findings at 2 days and 6 months post-reperfusion in patients with STEMI
| Female (n=87) | Male (n=237) | P value | |
| MRI finding 2 days post-MI | |||
| Infarct size (%LV mass), median (IQR) | 15.90 [4.90–24.28) | 16.50 [7.00–28.88) | 0.141* |
| LVESVi, mL/m2, median (IQR) | 32.45 [23.40–40.00) | 36.30 [27.40–46.30) | |
| LVEDVi, mL/m2, median (IQR) | 70.80 [63.70–80.60) | 80.60 [72.53–91.58) | |
| Microvascular obstruction present, n (%) | 37 (43) | 127 (54) | 0.078‡ |
| Microvascular obstruction extent (%LV mass), mean±SD | 1.96±3.95 | 3.25±5.32 | |
| Myocardial haemorrhage, n (%) | 17 (29) | 85 (45) | |
| T1 remote zone (ms), mean±SD | 968.46±24.97 | 958.74±24.64 | |
| T1 infarct zone, (ms), mean±SD | 1105.40±52.39 | 1091.20±51.04 | |
| T1 core zone, (ms), mean±SD | 1001.05±74.43 | 995.68±51.18 | 0.615† |
| T2 remote zone (ms), mean±SD | 50.07±2.11 | 49.62±2.04 | 0.088† |
| T2 infarct zone (ms), mean±SD | 62.45±4.91 | 63.04±5.22 | 0.356† |
| T2 core zone (ms), mean±SD | 53.10±4.68 | 54.15±4.87 | 0.204† |
| | |||
| Myocardial salvage index (%LV mass), median (IQR) | 64.20 [47.55–87.15) | 60.40 [43.80–82.30) | 0.169* |
| LVEF% at 6 months, mean±SD | 63.93±9.13 | 61.15±9.41 | |
| LVESVi at 6 months, mL/m2, median (IQR) | 26.55 [18.70–33.20) | 31.50 [22.68–40.93) | |
| LVEDVi at 6 months, mL/m2, median (IQR) | 74.25 [63.60–80.80) | 83.70 [72.75–94.55) | |
| Change in LVEDVi (6 months compared with 2 days), median (IQR) | 0.90 [−7.10 to 7.40) | 2.25 [−5.55 to 9.60) | 0.158* |
| Change in LVEDVi (6 months compared with 2 days≥20%), n (%) | 5 (6) | 15 (7) | 0.872‡ |
| Persistent myocardial haemorrhage, n (%): | |||
| None/resolved | 43 (88) | 121 (75) | 0.054‡ |
| T2 remote zone (ms), mean±SD | 49.94±2.48 | 49.64±2.28 | 0.328† |
| T2 infarct zone (ms), mean±SD | 56.41±3.95 | 56.05±4.24 | 0.512† |
| T2 core zone (ms), mean±SD | 45.72±4.31 | 47.80±3.57 | 0.194† |
LV volumes and ejection fraction on MRI at 2 days was available in 321 subjects. At 6 months, LV volumes were available in 294 subjects. Infarct size was available in 322 subjects on MRI at 2 days and 296 subjects at 6 months. Myocardial salvage index and LVEF at 6 months was available in 296 subjects. Presence/absence of microvascular obstruction was available in 324 subjects, extent of microvascular obstruction in 322 subjects, myocardial haemorrhage in 246 subjects and persistent myocardial haemorrhage in 211 subjects. T1 remote and infarct zone information was available in 288 subjects, and T1 core in 160 subjects. On MRI at 2 days, T2 remote/infarct zone information was available in 324 subjects, core zone in 192 subjects and at 6 months T2 remote, infarct, core zone was available in 297, 296 and 52 subjects, respectively.
*Mann-Whitney U test.
†Student’s t-test.
‡χ2 test.
LV, left ventricular; LVEDVi, LV end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESVi, LV end-systolic volume index; MI, myocardial infarction; STEMI, ST-segment elevation myocardial infarction.
Univariable and multivariable associations between female sex and (I) MRI surrogate outcomes and (II) acute reperfusion outcomes from the ECG, angiogram and invasive coronary physiology
| Crude | Adjusted | |||
| Infarct size (%LV mass) | −0.08 (−0.19 to 0.03) | 0.140 | −0.06 (−0.16 to 0.05) | 0.282 |
| LVEF% | 0.10 (−0.01 to 0.21) | 0.086 | 0.05 (−0.05 to 0.16) | 0.327 |
| LVESVi at 2 days, mL/m2 | −0.22 (−0.33 to −0.12) | −0.17 (−0.27 to −0.07) | ||
| LVEDVi at 2 days, mL/m2 | −0.30 (−0.40 to −0.19) | −0.26 (−0.36 to −0.20) | ||
| Microvascular obstruction present | 0.64 (0.39 to 1.05) | 0.079 | 0.60 (0.35 to 1.02) | 0.060 |
| Microvascular obstruction extent (%LV mass) | −0.12 (−0.22 to −0.01) | −0.10 (−0.21 to −0.01) | 0.077 | |
| Myocardial haemorrhage present | 0.50 (0.27 to 0.95) | 0.52 (0.26 to 1.03) | 0.060 | |
| T1 remote zone (ms) | 0.17 (0.06 to 0.29) | 0.18 (0.06 to 0.30) | ||
| T1 infarct zone (ms) | 0.12 (0.00 to 0.24) | 0.11 (−0.01 to 0.23) | 0.063 | |
| T1 core zone (ms) | 0.04 (−0.12 to 0.20) | 0.615 | 0.07 (−0.09 to 0.23) | 0.398 |
| T2 remote zone (ms) | 0.10 (−0.01 to 0.20) | 0.088 | 0.10 (−0.02 to 0.21) | 0.089 |
| T2 infarct zone (ms) | −0.05 (−0.16 to 0.06) | 0.356 | −0.06 (−0.18 to 0.06) | 0.319 |
| T2 core zone (ms) | −0.09 (−0.23 to 0.05) | 0.204 | −0.10 (−0.26 to 0.05) | 0.176 |
| Myocardial salvage index (%LV mass) | 0.08 (−0.03 to 0.20) | 0.151 | 0.08 (−0.04 to 0.20) | 0.206 |
| Infarct size (%LV mass) | −0.10 (−0.22 to 0.01) | 0.077 | −0.07 (−0.18 to 0.04) | 0.207 |
| LVEF% | 0.13 (0.02 to 0.25) | 0.11 (0.00 to 0.23) | 0.060 | |
| LVESVi at 6 months, mL/m2 | −0.21 (−0.32 to −0.10) | −0.19 (−0.31 to −0.08) | ||
| LVEDVi at 6 months, mL/m2 | −0.27 (−0.38 to −0.16) | −0.26 (−0.37 to −0.15) | ||
| Change in LVEDVi>20% | 0.92 (0.32 to 2.62) | 0.872 | −0.08 (−0.19 to 0.04) | 0.206 |
| Persistent myocardial haemorrhage present | 0.48 (0.21 to 1.08) | 0.075 | 0.47 (0.20 to 1.13) | 0.092 |
| T2 remote zone (ms) | 0.06 (−0.06 to 0.17) | 0.328 | 0.08 (−0.04 to 0.20) | 0.193 |
| T2 infarct zone (ms) | 0.04 (−0.08 to 0.15) | 0.512 | 0.04 (−0.08 to 0.16) | 0.558 |
| T2 core zone (ms) | −0.18 (−0.46 to 0.10) | 0.194 | 0.01 (−0.40 to 0.42) | 0.946 |
| TIMI frame count post-PCI | −0.15 (−0.26 to −0.04) | −0.17 (−0.28 to −0.05) | ||
| TIMI myocardial perfusion grade post-PCI ≤1 | 0.51 (0.28 to 0.93) | 0.52 (0.28 to 0.97) | ||
| IMR >40(U) | 0.92 (0.51 to 1.64) | 0.771 | 0.90 (0.49 to 1.66) | 0.744 |
| IMR(U) | −0.07 (−0.18 to 0.05) | 0.247 | −0.09 (−0.20 to 0.03) | 0.161 |
| CFR≤2 | 0.94 (0.47 to 1.89) | 0.871 | 1.11 (0.54 to 2.30) | 0.777 |
| CFR | −0.03 (−0.14 to 0.09) | 0.667 | −0.00 (−0.13 to 0.12) | 0.951 |
| Incomplete ST-segment resolution | 0.89 (0.44 to 1.80) | 0.743 | 1.17 (0.55 to 2.46) | 0.687 |
MRI outcomes at 6 months were adjusted for prescription of beta-blocker on discharge, eGFR, reperfusion strategy (thrombolysis vs no thrombolysis), culprit artery territory (LAD/left main vs circumflex vs right coronary artery), age and ischaemic time. All other outcomes were adjusted for eGFR, reperfusion strategy (thrombolysis vs no thrombolysis), culprit artery territory (LAD/left main vs circumflex vs right coronary artery), age and ischaemic time.
CFR, coronary flow reserve; eGFR, estimated glomerular filtration rate; IMR, Index of microcirculatory resistance; LV, left ventricular; LVEDVi, LV end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESVi, LV end-systolic volume index; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; TIMI, Thrombolysis in Myocardial Infarction.
Figure 2(A) Kaplan-Meier curve for MACE-free survival, after initial hospitalisation to 5-year follow-up. (B) Kaplan-Meier curve for survival free from all-cause death or the first heart failure hospitalisation to 5-year follow-up. MACE, major adverse cardiovascular event.